ACLARIS THERAPEUTICS INC (ACRS) Forecast, Price Target & Analyst Ratings
NASDAQ:ACRS • US00461U1051
3.67 USD
+0.28 (+8.26%)
At close: Mar 10, 2026
3.6736 USD
+0 (+0.1%)
Pre-Market: 3/11/2026, 9:25:06 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACLARIS THERAPEUTICS INC (ACRS).
Forecast Snapshot
Consensus Price Target
$8.16
+ 122.34% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$0.16
Revenue Estimate1.223M
ChartMill Buy Consensus
84.29%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.16
Upside
+ 122.34%
From current price of $3.67 to mean target of $8.16, Based on 14 analyst forecasts
Low
$2.02
Median
$7.14
High
$16.80
Price Target Revisions
1 Month
4.35%
3 Months
4.35%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for ACRS. The average price target is 8.16 USD. This implies a price increase of 122.34% is expected in the next year compared to the current price of 3.67.
The average price target has been revised upward by 4.35% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.29%
ACRS was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ACRS.
In the previous month the buy percentage consensus was at a similar level.
ACRS was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-28 | Wedbush | Initiate | Outperform |
| 2025-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-09 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-03-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-03-07 | ScotiaBank | Initiate | Sector Outperform |
| 2024-12-23 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2024-11-19 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2024-11-19 | BTIG | Upgrade | Neutral -> Buy |
| 2024-11-19 | Jefferies | Upgrade | Hold -> Buy |
| 2024-11-18 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-08-19 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-07-22 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-01-22 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-01-11 | BTIG | Downgrade | Buy -> Neutral |
| 2023-12-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-18 | Stifel | Maintains | Hold -> Hold |
| 2023-11-14 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-11-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-13 | William Blair | Downgrade | Outperform -> Market Perform |
| 2023-11-13 | Stifel | Downgrade | Buy -> Hold |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate-$0.16
Revenue Estimate1.223M
Revenue Q2Q-15.95%
EPS Q2Q-34.78%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
-47.87%
Revenue (3 Months)
-47.87%
EPS (1 Month)
-15.32%
EPS (3 Months)
-15.32%
Next Earnings Summary
ACRS is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.16 USD and the consensus revenue estimate is 1.22M USD.
The next earnings revenue estimate has been revised downward by 47.87% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.249M 5.04% | 18.72M -40.09% | 7.826M -58.19% | 5.141M -34.31% | 4.298M -16.40% | 6.319M 47.02% | 41M 548.84% | 132.8M 223.90% | 81.09M -38.94% | 237.66M 193.08% | 378.62M 59.31% | |
| EBITDA YoY % growth | -88.551M -4.98% | -51.52M 41.82% | -75.921M -47.36% | -83.36M -9.80% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -89.414M -5.01% | -52.327M 41.48% | -76.375M -45.96% | -80.877M -5.89% | -102.686M -26.97% | -103.116M -0.42% | -127.381M -23.53% | -131.703M -3.39% | -157.794M -19.81% | -31.62M 79.96% | 51.153M 261.77% | |
| Operating Margin | -286.13% | -279.52% | -975.91% | -1,573.17% | -2,389.16% | -1,631.84% | -310.69% | -99.17% | -194.59% | -13.30% | 13.51% | |
| EPS YoY % growth | -1.25 6.02% | -1.51 -20.80% | -0.53 64.90% | -0.66 -23.87% | -0.70 -7.13% | -0.82 -16.32% | -0.89 -9.31% | -0.46 48.29% | -0.73 -58.84% | 0.28 137.50% | 1.10 300.00% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 -34.78% | -0.16 -25.09% | -0.13 -10.50% | -0.15 9.16% | -0.13 20.54% | -0.11 35.39% | -0.08 41.54% | -0.07 52.98% |
| Revenue Q2Q % growth | 1.223M -15.95% | 1.238M -30.33% | 2.372M -28.10% | 2.423M 87.10% | 3.365M 175.14% | 3.365M 171.81% | 3.365M 41.86% | 3.365M 38.88% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.489M -13.30% | -21.202M -15.18% | -17.901M -4.39% | -21.93M 3.54% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-15.57%
EPS Next 5 Year
2.43%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
-9.89%
Revenue Next 5 Year
72.73%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
ACLARIS THERAPEUTICS INC / ACRS Forecast FAQ
Can you provide the average price target for ACLARIS THERAPEUTICS INC stock?
14 analysts have analysed ACRS and the average price target is 8.16 USD. This implies a price increase of 122.34% is expected in the next year compared to the current price of 3.67.
When does ACLARIS THERAPEUTICS INC (ACRS) report earnings?
ACLARIS THERAPEUTICS INC (ACRS) will report earnings on 2026-05-06.
Can you provide the consensus estimates for ACLARIS THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of ACLARIS THERAPEUTICS INC (ACRS) is -0.16 USD and the consensus revenue estimate is 1.22M USD.
What is the expected long term growth rate for ACRS stock?
The expected long term growth rate for ACLARIS THERAPEUTICS INC (ACRS) is -9.89%.